HERMES PHARMA announces €25 million investment to bolster capacity

September 26, 2023

The investment will help the company meet soaring demand for user-friendly oral dosage form development and manufacturing

Site WolfsbergSite WolfratshausenHERMES PHARMA, the leading expert in user-friendly oral dosage forms, has announced it will invest €25 million to further bolster its manufacturing capabilities. The investment will arm the company with new equipment, increased production and storage capacity, and greater operational efficiency to meet the rapidly growing market demand for user-friendly oral dosage forms. As a result, HERMES PHARMA will be able to further drive future growth, while helping new and existing customers to realize theirs.

The pharmaceutical industry has long seen traditional tablets and capsules as the ‘gold standard’ of oral dosage forms. However, around 50% of people struggle to take them. Consequently, demand for easy-to-swallow oral dosage forms, such as orally disintegrating granules (ODGs), chewable tablets, lozenges, instant drinks, and effervescents, is soaring, with healthcare companies seeking to add them to their portfolios.

For more than twenty years, HERMES PHARMA has specialized in developing and manufacturing user-friendly oral dosage forms, with services covering the entire value chain — from new product development through to manufacturing, clinical studies, and regulatory support. To address the rapidly growing demand for these dosage forms, HERMES PHARMA will invest €25 million in its specialist manufacturing plants, powering the company’s growth while unlocking greater scale, flexibility, and cost-efficiency for customers.

More specifically, the investment will add

  • new, large-volume coating equipment to support growing need for advanced taste-masking
  • new filling and packaging lines for ODGs and instant drinks
  • expanded Good Manufacturing Practice (GMP) manufacturing space
  • greater GMP storage capacity
  • optimized flow of inventory/goods on the shop floor

Andreas Ulrich COO HERMES PHARMA“As pharmaceutical companies race to find ways to better serve patients and differentiate themselves in a competitive market, we’re seeing unprecedented demand for more patient-centric products,” said Dr Andreas Ulrich, COO of HERMES PHARMA . “Our latest investment will help us meet that demand, delivering ever greater service for our customers, while also helping us serve new customers across different market segments. We look forward to getting new and improved user-friendly dosage forms to patients quickly and more efficiently than ever before.”

To find out more about HERMES PHARMA’s manufacturing capabilities, please visit the website.


HERMES PHARMA is the leading expert in developing and manufacturing user-friendly oral dosage forms, including effervescent and chewable tablets, instant drinks, lozenges, orally disintegrating granules and the newly developed HERMES NutriCaps. As a contract development and manufacturing organization (CDMO), we offer customized services along the entire pharmaceutical value chain, from new product development and formulation to manufacturing and regulatory support. For more than 40 years, leading healthcare companies around the globe have worked with HERMES PHARMA to expand their pharmaceutical and nutraceutical product lines as well as to grow their brands.

Further information is available at

Categories: Drug Discovery & Development, Pharma, Corporate, Finance & Investor
Browse more news

Recent releases